Sprenger, Jana

[["dc.bibliographiccitation.firstpage","435"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","435 Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of 3/ 3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.435"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S430"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H.A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71771-3"],["dc.identifier.pii","S0959804911717713"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110450"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6126 POSTER Thymidylate Synthase as Biomarker in Rectal Cancer Patients After 5-FU-based Radiochemotherapy – Evaluation of the Prognostic Capacity in Pre-treatment Biopsies and Resected Adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S431"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rödel, F."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Yildirim, M."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71775-0"],["dc.identifier.pii","S0959804911717750"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110451"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6130 POSTER Survivin Expression in Rectal Cancer During Preoperative Radiochemotherapy and Its Impact on Metastasis and Patients' Survival"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e14115"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","e14115"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rodel, F."],["dc.contributor.author","Rothe, H."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:18Z"],["dc.date.available","2022-06-08T07:57:18Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1200/jco.2010.28.15_suppl.e14115"],["dc.identifier.isi","000208852000619"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110052"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Survivin: A potential predictive and prognostic marker in multimodal rectal cancer therapy."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","483"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","483"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rödel, F."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Yildrim, M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","483 Background: Valid molecular markers need to be implemented in clinical trials to fulfill the demand of a risk-adapted and more individualized multimodal therapy of locally advanced primary rectal cancer. In the present study the expression of the inhibitor-of-apoptosis (IAP) protein Survivin was evaluated in pre-treatment biopsies and corresponding post-treatment resection specimens, and was correlated to histo-pathological tumor characteristics and clinical follow-up. Methods: 116 patients with stage II/III rectal cancer treated with 5-FU-based neoadjuvant radiochemotherapy (RCT) within the German Rectal Cancer Trials were investigated. Survivin expression in pre-treatment biopsies and surgical resection specimens were determined by immunohistochemistry by two independent institutions and correlated with histopathologic parameters, tumor recurrences, disease-free and overall cancer-specific survival. Results: In pre-treatment biopsies, a higher Survivin expression correlated with advanced ypT (p=0.026) and ypUICC (p=0.05) stage as well as decreased disease-free survival (p=0.038) after preoperative RCT. High post-treatment Survivin levels were associated with advanced ypT stage (p=0.03) and residual lymph node metastases (p=0.04). Moreover, neoadjuvant RCT resulted in a significant down-regulation of Survivin expression (p < 0.0001). A failure of RCT-induced down-regulation was associated with development of distant metastases (p=0.0056) and cancer-related death (p=0.026), and was significantly correlated with disease-free (p=0.011 /0.02 ) and cancer-specific survival (p=0.0017 /0.01 ) in uni - and multivariate analyses. Conclusions: Survivin expression displays a marker with prognostic validity in rectal cancers. These results underline the usefulness of Survivin to monitor individual response to RCT in rectal cancer, and encourage anti-Survivin strategies in multimodal rectal cancer therapy within future randomised clinical trials. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110057"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Association of survivin expression following neoadjuvant radiochemotherapy in rectal cancer with distant metastases and survival."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]